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Abstract
Background: There are currently no promising therapies available to treat or prevent peripheral neuropathy (PN)
induced by anticancer drugs in a cumulative dose-dependent manner. In this study, we investigated the efficacy of
regional cooling of hands and feet in preventing paclitaxel (PTX)-induced PN.
Methods: Patients with gynecologic cancer who received a tri-weekly cycle of chemotherapy including PTX at doses of
150–175 mg/m2 were included in this study. Regional cooling was performed by covering patient hands and feet with
cold insulators during PTX administration (regional cooling group). The primary end-point was ≥grade 2 PN evaluated by
the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. The secondary end-points were the frequency of PN
therapeutic drug use, PTX dose reduction due to PN, and adverse events due to regional cooling. The efficacy of regional
cooling was compared with data retrospectively extracted from the medical records of patients who did not receive
regional cooling (control group). All end-points were evaluated for up to six cycles.
Results: There were 40 and 142 patients in the regional cooling and control groups, respectively. As a primary end-point,
incidences of ≥grade 2 PN in the fourth to sixth cycles were significantly lower than that in the cooling group (5.0–9.1 %
vs. 19.8–31.6 %, p < 0.05 after the fourth cycle and p < 0.01 after the fifth cycle). Among secondary end-points, neither
the use of PN therapeutic drugs nor the PTX dose reduction due to PN were significantly lower in the cooling group
than in the control group (27.5 vs. 36.6 %, p = 0.378 and 5.0 vs. 3.5 %, p = 0.645, respectively). There were no serious
regional cooling-associated adverse events such as frostbite.
Conclusions: Regional cooling of hands and feet during PTX administration might have good effectiveness and
tolerability, suggesting this approach as a potentially effective supportive care to prevent PTX-induced PN.
Trial registration: The trial approval number in the institution; H25-26. Registered 5 June 2014.
Keywords: Regional cooling, Peripheral neuropathy, Paclitaxel, Gynecologic cancer, Chemotherapy
Background
Peripheral neuropathy (PN) is caused by the administra-
tion of anticancer drugs such as taxane, platinum, and
vinca alkaloid. The symptoms of PN begin as glove/
sock-type hypesthesia, hyperesthesia, or dysesthesia of
peripheral areas, such as the hands and feet [1]. These
symptoms spread and increase in severity in a cumula-
tive dose-dependent manner. Activities of daily living
(ADLs), such as writing, getting dressed, and eating, are
gradually affected. When PN reaches a severe stage,
motor nerve disorders of the hands and feet inhibit
some ADLs, such as walking; these can persist for a long
time, greatly impairing the quality of life [2, 3]. Reduc-
tion or discontinuation of PN-inducing anticancer drugs
based on appropriate evaluation and early detection is
an important component of the management of
chemotherapy.
One of anticancer drug that induces PN is paclitaxel
(PTX). In several phase III studies using tri-weekly
TC therapy [PTX: 175–180 mg/m2 and carboplatin
(CBDCA): AUC= 5–6] and tri-weekly TP therapy [PTX:
175 mg/m2 and cisplatin (CDDP): 75 mg/m2] as standard
chemotherapy regimens for gynecologic cancer, the
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frequencies of grade ≥3 PN neurosensory and neuromotor
symptoms were in the range of 6–14 % and 2–7 %, re-
spectively [4–7].
High plasma PTX concentrations of 0.05 μmol/L or more
have been reported to be associated with the development
of PN [8]. This previously reported high PTX blood con-
centration was observed for 24 h in the tri-weekly PTX
regimen (including more than 175 mg/m2 PTX) [9]. There-
fore, a decrease in the plasma PTX concentration in periph-
eral regions might prevent to develop PN.
Regional cooling is one of the methods used to reduce
peripheral exposure to anticancer drugs in clinical
practice. However, the effect of regional cooling in pre-
venting chemotherapy-induced PN has not been investi-
gated. In this study, we investigated the effect of hand
and foot cooling on the development of PN in patients




Patients with gynecologic cancer (ovarian, cervical, or
endometrial cancer) who received chemotherapy includ-
ing PTX at doses of 150–175 mg/m2 for 3 h every
3 weeks, concomitant with CBDCA or CDDP, at Iwate
Medical University Hospital between July 2014 and
November 2015 were eligible for intervention in this
study. Patients with preexisting subjective PN symptoms
prior to chemotherapy initiation and those with poten-
tial PN due to prior chemotherapy regimens including
taxane or platinum by a recurrence of disease within 1
year were excluded. Patients with new diagnosis and
those with cancer recurrence more than 1 year after last
chemotherapy received regional cooling (regional cool-
ing group) after consent for participation in this study
was obtained. Patients were not randomized during the
intervention period. The effect of regional cooling was
compared with historical control data which was retro-
spectively extracted from the medical records of patients
who received similar chemotherapy regimens during the
period before regional cooling intervention (April 2011–
June 2014, control group). In this historical control co-
hort, patients with recurrent disease within 1 year prior
to enrollment in this study and those with subjective PN
symptoms before chemotherapy initiation were ex-
cluded. As an exclusion criteria for the analysis, patients
who discontinued chemotherapy early during treatment
(<4 cycles) in both the regional cooling and control
groups were excluded from analysis. Furthermore, given
that diabetes, current neuropathy, and past platinum use
were reported as risk factors for PN [10], patients with a
medical history of diabetes, rheumatoid arthritis, lymph-
edema, and/or treatment for PN before chemotherapy
initiation were also excluded from the analysis.
Chemotherapy regimen
The details of each chemotherapy regimen were as fol-
lows: TC ± bevacizumab (BV); PTX 175 mg/m2 +
CBDCA AUC= 6 ± BV 15 mg/kg, TP; PTX 175 mg/m2 +
CDDP 75 mg/m2, TEC; PTX 150 mg/m2 + Epirubicin
50 mg/m2 + CBDCA AUC= 5; and TAC; PTX 150 mg/
m2 + Adriamycin 45 mg/m2 + CBDCA, AUC= 5.
Method of regional cooling
Regional cooling was performed using cold insulators as
shown in Fig. 1 (Elasto-Gel™ mitts for hands: TM7008,
and slippers for feet: SL3000; Southwest Technologies,
Inc., North Kansas City, MO, USA), which were pre-
cooled to −30 °C before use. The insulators were fitted
on both hands and feet for 3 h under PTX administra-
tion. The cold insulators were changed hourly.
Evaluation criteria and timing
The severity of PN was evaluated by a physician or a
pharmacist using the Common Terminology Criteria for
Adverse Events (CTCAE) v4.0 before the start of each
chemotherapy cycle as well as 3 weeks after the last
chemotherapy in the regional cooling group. Retrospect-
ive data collected from the medical records of the con-
trol group also contained information on PN symptoms
from time points comparable to those of the cooling
group. Evaluation for PN symptoms was performed for
up to six cycles.
Primary and secondary end-point
The primary end-point was ≥grade 2 PN. The secondary
end-points were the frequency of PN therapeutic drugs
use (with therapeutics including pregabalin, gabapentin,
duloxetine, Gosha-jinki-gan, mecobalamin, tramadol
hydrochloride, and opioids), PTX dose reduction due to
PN, and adverse events of regional cooling.
Statistical analysis
Background information of patients such as age, number
of chemotherapy cycles, body surface area, initial PTX
dose, cumulative PTX dose, and cumulative platinum
dose were presented as means ± standard deviation, and
differences were analyzed by unpaired t test. Differences
in type of cancer, regimen, and the presence of concomi-
tant platinum use were analyzed by the chi-square test.
The incidence of ≥grade 2 PN, PN therapeutic drug use,
and PTX reduction due to PN were analyzed by the chi-
square test. Hazard ratios of less than 5 % were
considered statistically significant. Statistical analyses
were performed using Excel® Statistics 2012 software
(Social Information Service, Tokyo, Japan).
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Results
Patient background
A consort diagram for this study is shown in Fig. 2.
There were 95 patients who received chemotherapy in-
cluding tri-weekly PTX concomitant with CBDCA or
CDDP from July 2014 to November 2015. Among these,
32 patients were excluded due to treatment for recur-
rence within one year or PN resulting from previous
chemotherapy (n = 29) or due to lack of sufficient infor-
mation (n = 3). Therefore, 63 patients were started on re-
gional cooling with chemotherapy initiation. Of these, 23
patients were excluded from the final analysis due to
early chemotherapy discontinuance (<4 cycles, n = 10),
history of diabetes (n = 7), use of the PN therapeutic
drug before chemotherapy initiation (n = 2), history of
rheumatoid arthritis (n = 2), severe lymphedema (n = 1),
and regional cooling secession (n = 1); therefore, a total
of 40 patients in the regional cooling group were in-
cluded in the final analysis.
In the control group, there were 225 patients who re-
ceived chemotherapy including tri-weekly PTX con-
comitant with CBDCA or CDDP from April 2011 to
June 2014. Among these, 83 patients were excluded due
to early chemotherapy discontinuance (<4 cycles, n = 37),
treatment for recurrence within one year or PN due to pre-
vious chemotherapy (n = 23), history of diabetes (n = 18),
Fig. 1 Cold insulators for hands (a) and feet (b). Figure 1 indicated cold insulators used in this study. The
pre-cooled insulators were fitted on both hands and feet. The insulators were changed hourly
Fig. 2 Consort diagram in this study. Figure 2 indicated the consort diagram of this study. Sixty three patients agreed to the participation in the
study and received regional cooling. Forty patients who were able to continue chemotherapy were analyzed. As the control group, 225 patients
who received similar chemotherapy in the period before intervention of the regional cooling were retrospectively extracted from medical chart.
One hundred-forty two patients were analyzed
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rheumatoid arthritis (n = 3), use of the PN therapeutic drug
before chemotherapy initiation (n =1), and severe lymph-
edema (n = 1); therefore, a total of 142 patients in the con-
trol group were included in the final analysis.
Background characteristics of patients are represented
in Table 1. There were significant differences in the dis-
tribution of regimens and use of concomitant platinum
between the two groups (p = 0.004 and p = 0.006, re-
spectively). However, there were no significant differ-
ences in age, cancer type, number of chemotherapy
cycles, body surface area, PTX, and platinum dose be-
tween the two groups.
Primary end-point
The incidence rate of ≥grade 2 PN in the regional cool-
ing group (5.0–9.1 %) was significantly lower than that
observed in the control group (22.5–35.8 %, p < 0.05 in
the fourth cycle and p < 0.01 after the fifth cycle, Fig. 3).
Secondary end-points
There was no significant difference in the frequency of PN
therapeutic drug use in the regional cooling group than in
the control group (27.5 vs. 36.6 %, P = 0.378, Table 2). Spe-
cifically, the following medications were prescribed for PN
therapeutic drugs (There is, with some patients receiving
combination therapy: Gosha-jinki-gan (n = 7), mecobala-
min (n = 3), pregabalin (n = 1), oxycodone hydrochloride
(n = 1), and duloxetine hydrochloride (n = 1) in the re-
gional cooling group; pregabalin (n = 22), Gosha-jinki-gan
(n = 22), mecobalamin (n = 10), and tramadol hydrochlor-
ide (n = 1) in the control group. There was also no sig-
nificant difference in the frequency of PTX dose
reduction due to PN between the two groups (5.0 vs.
3.5 %, p = 0.645, Table 2). Severe adverse events related
to regional cooling such as frostbite were not observed.
However, one patient discontinued regional cooling half-
way through a cycle (at three cycle) because of cold-
induced pain.
Discussion
PN induced by PTX is thought to be reversible because
axons are reproduced upon discontinuation of the drug.
This is different for CDDP-induced irreversible PN be-
cause of direct damage of the perikaryon [11, 12]. Most
patients that were administered PTX suffer PN for a long
time. The PTX-induced PN develops depending on in-
creasing once dose and cumulative dose of PTX, shorten-
ing of PTX infusion time. For example, in a controlled
trial using a fixed dose intensity of PTX in ovarian cancer,
there was a significantly higher incidence of grade 3 PN in
patients administered 200 mg/m2/3 weeks than in those
administered 67 mg/m2/week (29 vs. 11 %, P < 0.001) [13].
In addition, in a systematic review, PN was reported to be
more common upon the 3 h administration of PTX than
upon 24 h administration [14]. The average cumulative
dose at which grade ≥2 PN developed was reported to be
715 mg/m2 when 175 mg/m2 PTX was given every 3 weeks
in patients with metastatic breast cancer [15]. For gyneco-
logic cancer, TC regimen including high-dose PTX ad-
ministration was performed every 3 weeks as standard
chemotherapy. It is important that these TC regimens
generally be completed within four to six cycles [16]. As
the cumulative PTX dose in this clinical practice is
700 mg/m2 or more, PN is an unavoidable adverse event.
Few drugs have been used to prevent or relieve
chemotherapy-induced PN. Classically, antiepileptics or
Table 1 Patients background
Control group (n = 142) Cooling group (n = 40) P-value
Age (min-max) 59.7 ± 11.5 (35–84) 56.5 ± 10.4 (32–77) 0.144
Cancer type Ovarian (n = 80)
Cervical (n = 14)
Endometrial (n = 48)
Ovarian (n = 23)
Cervical (n = 9)
Endometrial (n = 8)
0.053
Regimen TC ± BV (n = 137)
TP (n = 2)
TAC or TEC (n = 3)
TC ± BV (n = 35)
TP (n = 5)
0.004
Concomitant platinum CBDCA (n = 140)
CDDP (n = 2)
CBDCA (n = 35)
CDDP (n = 5)
0.006
Cycle 5.9 ± 0.4 5.9 ± 0.4 0.624
Body-surface area (m2) 1.526 ± 0.151 1.483 ± 0.127 0.233
Initial PTX dose (mg/m2) 170.2 ± 6.9 171.2 ± 8.4 0.944
Cumulative PTX dose (mg/m2) 997.4 ± 78.9 1010.1 ± 95.1 0.483
Cumulative Platinum dose (mg/m2) CBDCA; 2291.3 ± 391.7
CDDP; 324.8 ± 34.3
CBDCA; 2332.2 ± 301.6
CDDP; 295.7 ± 5.5
0.565
0.311
The value of age, cycle, body-surface area, initial PTX dose, cumulative PTX dose, and cumulative platinum dose were indicated as means ± standard deviation
and its p values were calculated by unpaired t-test. The p value of cancer type, regimen, concomitant platinum were calculated by chi-square test. PTX paclitaxel,
CBDCA carboplatin, CDDP cisplatin, TC ± BV bevacizumab ± paclitaxel + carboplatin, TP paclitaxel + cisplatin, TAC paclitaxel + doxorubicin + carboplatin,
TEC paclitaxel + epirubicin + carboplatin
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antidepressants such as carbamazepine and amitriptyline
have been administered, but recently gabapentin and
duloxetine have been widely used [17–19]. However,
these drugs do not seem to provide much benefit be-
cause of their low efficacy and serious adverse effects
such as somnolence. Only duloxetine was moderately
recommended for therapeutic use for chemotherapy-
induced PN in the guidelines of the American Society of
Clinical Oncology [20]. However, taxane-induced PN
might be more difficult to than oxaliplatin-induced PN,
even if duloxetine is used [21]. Therefore, non-
pharmacological therapy with therapeutic efficacy and
few adverse effects was expected for chemotherapy-
induced PN.
In this study, we investigated the efficacy of regional
cooling as a potential non-pharmacological prophylactic
therapy for PTX-induced PN. Our results showed that
the incidence rates of ≥grade 2 PN were decreased with
regional cooling. In particular, there was significantly
better cooling efficiency during and after the fourth
cycle, at which point PN became severe. Unfortunately,
the prescription rates of therapeutic drugs for PN or the
frequency of PTX dose reduction due to PN were not
significantly lower in the regional cooling group. How-
ever, it was thought that inhibition of ≥grade 2 PN by re-
gional cooling was not likely due to the use of these
relief drugs and dose reduction of PTX.
The prevention of PN by regional cooling might result
from a decrease in regional PTX exposure. In a previous
study, experimental cooling of the palms of healthy sub-
jects to 19 °C led to a 53–60 % decrease in blood flow to
the palms [22]. Cooling mitts and slippers used in this
study decreased the surface temperature of hands and
feet by 10–20 °C, which was maintained for up to 1 h in
a small number of healthy subjects as determined by
thermography. Subsequent studies have successfully
reported the use of regional cooling as a supportive
modality to relieve adverse effects associated with anti-
cancer drugs such as hand and foot cooling for
docetaxel-induced nail toxicity [23] and hand-foot syn-
drome due to pegylated liposomal doxorubicin [24], cool
cap for alopecia [25], and cryotherapy with intraoral ice
chips for 5-fluorouracil- or melphalan-induced oral mu-
cositis [26, 27]. A similar mechanism might be at play in
the protective effect of regional cooling against PN.
The following limitations should be considered during
the interpretation of the present study. First, there were
differences in regimens and the use of concomitant plat-
inum between the control and regional cooling groups.
In majority of the cases, the etiology of PN was consid-
ered to be due to PTX; however, platinum might also
have contributed to the development of PN in some pa-
tients. Specifically, PN develops at cumulative CDDP
Fig. 3 Effect of the regional cooling on the incidence of Grade ≥2 PN. Figure 3 indicated the incidence of Grade ≥2 PN. The black bar indicated
the PN incidence of control group (n = 142) in each cycle. The white bar indicated the PN incidence of regional cooling group (n = 40) in each
cycle. The comparison of the both groups in each cycle performed by a chi-square test
Table 2 Effect of the regional cooling on the prescription of




group (n = 40)
p-value
Prescription of the PN
therapeutic drug※
52 (36.6 %) 11 (27.5 %) P = 0.378
PTX doses reduction
due to PN
5 (3.5 %) 2 (5.0 %) P = 0.645
PN Peripheral neuropathy. The p value indicated hazard ratio of the chi-square test
※pregabalin, duloxetine hydrochloride, mecobalamin, gosha-jinki-gan,
tramadol, oxycodone
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doses of 250–500 mg/m2 [28]. Seven patients in this
study were administered CDDP, with a mean cumulative
dose of 435 mg/m2, and two of these patients developed
≥grade 2 PN. Conversely, CBDCA was reported to have
4–6 % lower incidence of PN than CDDP [29], and the
difference in the frequency of PN induction by different
platinum drugs might have influenced the results. An-
other limitation of the present study was the evaluation
method, which was conducted by a medical professional,
which might have led to a lack of objectivity in evalu-
ation of patients exhibiting low-level PN symptoms [30].
It was possible that the focus of the medical professional
was on the recognition of potential PN symptoms during
evaluation of patients in the regional cooling group who
were enrolled in the intervention, leading to more fre-
quent identification of PN symptoms in this group than
in the control group. The regional cooling intervention
group was not masked. Given that regional cooling was
predicted to be effective by the evaluator, PN might be
underestimated, leading to a bias during evaluation. Fu-
ture investigation with modified designs such as cooling
only specific hand and foot in the same patient should
resolve this concern. One of the two previous studies in-
vestigating docetaxel-associated nail toxicity using a
similar design found that the incidence of ≥grade 1
fingernail toxicity was significantly lower in the cooled
hand than in the non-cooled hand (11 vs. 51 %, p < 0.001)
[31]. The outcome of the other study examining toenail
toxicity was similar (0 vs. 21 %, p = 0.002) [23]. While a
similar study design would resolve potential bias, such an
approach inadvertently would lead to ethical concerns by
allowing for the development of PN on one hand and foot
to examine the efficacy of the intervention in the re-
maining hand and foot.
The clinical evidence of this study was weak as it was
not a prospective randomize-controlled study. Therefore,
the efficacy of regional cooling for PN should be investi-
gated by future prospective randomized comparison
with a non-cooling group in future studies.
Conclusions
This study was the first to suggest that regional cooling of
the hands and feet are effective for the prophylaxis of
PTX-induced PN. Regional cooling might be well-
tolerated supportive care with few serious adverse effects
because it is a non-pharmacological therapy. The efficacy
of regional cooling should be further investigated by a ran-
domized comparison.
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